Please Wait...

Ronald Van Heertum

Translation skills

Main profile

Ronald Van Heertum, MD
Vice President of Molecular Imaging

Dr. Van Heertum is responsible for the management and implementation of all aspects of Molecular Imaging. Prior to coming to BioClinica, Dr. Van Heertum was Professor and Executive Vice Chairman/CAO, Department of Radiology at Columbia University College of Physicians & Surgeons as well as Director of Nuclear Medicine and PET. In this position he participated in many clinical trials in oncology, neurology, and psychiatry and established an international reputation in SPECT and PET imaging. He has authored or co-authored over 200 publications and is the editor of a book on Brain Imaging that is now in its 4th Edition. He has been an active member of the RSNA, American College of Radiology where he is an FACR and the Society of Nuclear Medicine.

Authored Publications

Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, Sokol L, Agarwal R, Strafaci JA, O'Neal M.  Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.  Dovepress.  13 June 2017 Volume 2017:11 Pages 1719—1728.

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Design, Development and Therapy 2015:9 5215–5223.

Blogs

Brain scan

I recently returned from the 6th Annual Clinical Trials in Alzheimer's Disease (CTAD) conference in San Diego. At the meeting, I had a chance to catch up on some of the latest scientific advances for the detection and treatment of AD. A recurring theme for improving the diagnosis and prognosis of AD is the increased use of biomarker data.

What do you get when you combine a molecular diagnostic agent with a targeted therapeutic? A powerful new tool paving the path to personalized medicine called a Theranostic. The basic architecture of a theranostic is as follows:

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (10 hours ago)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (15 hours ago)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (15 hours ago)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (17 hours ago)
Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will… https://t.co/BX6wzXctMm
bioclinica (3 days ago)
Let's talk oncology clinical trials at #ESMO18 ! Tap the knowledge of medical & scientific experts @bioclinica who'… https://t.co/RlTjGND5Qg
bioclinica (4 days ago)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner